Anzeige
Mehr »
Samstag, 23.05.2026 - Börsentäglich über 12.000 News
Niemand hat diese Kombination je gesehen: Wolfram, Indium & 2.370 g/t Silber bei 0,13
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40CM8 | ISIN: KYG3314S1066 | Ticker-Symbol: 5UD
Frankfurt
22.05.26 | 15:25
0,098 Euro
-5,34 % -0,006
Branche
Gesundheitswesen
Aktienmarkt
ASIEN
1-Jahres-Chart
FANGZHOU INC Chart 1 Jahr
5-Tage-Chart
FANGZHOU INC 5-Tage-Chart

Aktuelle News zur FANGZHOU Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrFANGZHOU JIANKE (06086): INVITATION LETTER TO REGISTERED SHAREHOLDERS FOR ONLINE ATTENDANCE AT 2026 ANNUAL GENERAL MEETING-
FrFANGZHOU JIANKE (06086): FORM OF PROXY ANNUAL GENERAL MEETING TO BE HELD ON JUNE 16, 2026 OR ANY ADJOURNMENT OR POSTPONEMENT THEREOF-
FrFANGZHOU JIANKE (06086): INVITATION LETTER TO NON-REGISTERED HOLDERS FOR ONLINE ATTENDANCE AT 2026 ANNUAL GENERAL MEETING-
FrFANGZHOU JIANKE (06086): PROPOSALS FOR GENERAL MANDATE TO ISSUE SHARES AND REPURCHASE MANDATE TO REPURCHASE SHARES AND RE-ELECTION OF RETIRING DIRECTORS ...-
FrFANGZHOU JIANKE (06086): NOTICE OF ANNUAL GENERAL MEETING1
FANGZHOU Aktie jetzt für 0€ handeln
FrFANGZHOU JIANKE (06086): PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND ADOPTION OF THE AMENDED AND RESTATED ARTICLES OF ASSOCIATION1
DiFangzhou Inc.: Fangzhou Ranked among 2025 Guangzhou AI Innovation "Most Promising Enterprises" for AI-Powered Chronic Disease Services1
14.05.Fangzhou und Tenry Pharmaceutical kooperieren bei KI-gestütztem Diabetes-Management1
14.05.Fangzhou partners with Tenry Pharmaceutical on diabetes care1
14.05.Fangzhou Inc.: Fangzhou and Tenry Pharmaceutical Forge Strategic Partnership to Advance AI-Powered Chronic Disease Care115SHANGHAI, May 14, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, and Shanghai Tenry Pharmaceutical...
► Artikel lesen
27.04.Fangzhou Inc.: Fangzhou Publishes 2025 Annual Report, Advancing AI-Powered Chronic Care Strategy for 2026292SHANGHAI, April 27, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, published its 2025 Annual Report...
► Artikel lesen
24.04.FANGZHOU JIANKE (06086): 2025 ANNUAL REPORT-
26.03.Fangzhou Inc. Appoints Healthcare Industry Veteran Wang Haijiao as Chief Executive Officer Following a Year of Record Growth and Profitability162SHANGHAI, March 26, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, today announced the appointment...
► Artikel lesen
26.03.FANGZHOU JIANKE (06086): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS1
26.03.FANGZHOU JIANKE (06086): APPOINTMENT OF CHIEF EXECUTIVE OFFICER AND EXECUTIVE DIRECTOR 1
19.03.Fangzhou Inc.: Fangzhou Reports Robust 2025 Financial Results, Boosted by AI Chronic Care Strategy649SHANGHAI, March 19, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, reported its 2025 annual results...
► Artikel lesen
19.03.FANGZHOU JIANKE (06086): ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 20251
09.03.FANGZHOU JIANKE (06086): DATE OF BOARD MEETING2
01.03.Fangzhou, Youcare Partner To Advance AI In Chronic Disease Care1
28.02.Fangzhou Inc.: Fangzhou and Youcare Pharmaceutical Group Form Strategic Alliance to Advance AI-Driven Chronic Care Services961BEIJING, Feb. 28, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, has signed a strategic collaboration...
► Artikel lesen
Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1